Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...

AstraZeneca is making a $1bn investment for the long term, but what lies in store for investors over the next 12 months? Here are the latest forecasts.

GAITHERSBURG, Md. (DC News Now) — AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a groundbreaking approach to fighting cancer. The ...

AZN to Acquire EsoBiotec; EU Nod for Imfinzi Expanded Use AstraZeneca announced a definitive agreement to acquire Belgium-based, EsoBiotec, a leading vivo cell therapy company for a total ...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. The UK ...

Multinational pharmaceutical company AstraZeneca plc has entered into a definitive agreement to acquire the Belgian biotech company EsoBiotec. This is reported in a press release from AstraZeneca. The ...

AstraZeneca (AZ) has announced that it will be expanding its cell therapy capabilities by acquiring EsoBiotec for up to $1bn.

AstraZeneca, a global, science-led biopharmaceutical company, has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has ...

Covington & Burling's London operation has advised pharmaceuticals giant AstraZeneca on its $1 billion acquisition of EsoBiotec, a Belgian biotechnology company specialising in vivo cell therapies.